Publication:
Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group

Simple item page
dc.contributor.authorEscobar, Alejandro
dc.contributor.authorReyes, Felipe
dc.contributor.authorAcevedo, Mónica
dc.contributor.authorAlonso, Luis
dc.contributor.authorValiente, Fernando
dc.contributor.authorSoto, Ricardo
dc.contributor.authorPortillo, Hugo
dc.contributor.authorGatica, Jimena
dc.contributor.authorFlores, Iván
dc.contributor.authorNova, Estefanía
dc.contributor.authorBarrera, Carlos
dc.contributor.authorBono, María
dc.contributor.authorVargas, Leonardo
dc.contributor.authorSimon, Valeska
dc.contributor.authorLeiva, Elias
dc.contributor.authorVial, Cecilia
dc.contributor.authorHormazábal, Juan
dc.contributor.authorJimena, Lina
dc.contributor.authorValdés, Daniel
dc.contributor.authorSandino, Ana
dc.contributor.authorImarai, Mónica
dc.contributor.authorAcuña, Claudio
dc.date.accessioned2023-05-02T16:09:26Z
dc.date.available2023-05-02T16:09:26Z
dc.date.issued2022
dc.description.abstractCoronaVac vaccine from Sinovac Life Science is currently being used in several countries. In Chile, the effectiveness of preventing hospitalization is higher than 80% with a vaccination schedule. However, to date, there are no data about immune response induction or specific memory. For this reason, we recruited 15 volunteers without previous suspected/diagnosed COVID-19 and with negative PCR over time to evaluate the immune response to CoronaVac 28 and 90 days after the second immunization (dpi). The CoronaVac administration induces total and neutralizing anti-spike antibodies in all vaccinated volunteers at 28 and 90 dpi. Furthermore, using ELISpot analysis to assay cellular immune responses against SARS-CoV-2 spike protein, we found an increase in IFN-gamma- and Granzyme B-producing cells in vaccinated volunteers at 28 and 90 dpi. Together, our results indicate that CoronaVac induces a robust humoral immune response and cellular immune memory of at least 90 dpi.
dc.description.versionVersión Publicada
dc.identifier.citationEscobar A, Reyes-López FE, Acevedo ML, Alonso-Palomares L, Valiente-Echeverría F, Soto-Rifo R, Portillo H, Gatica J, Flores I, Nova-Lamperti E, Barrera-Avalos C, Bono MR, Vargas L, Simon V, Leiva-Salcedo E, Vial C, Hormazabal J, Cortes LJ, Valdés D, Sandino AM, Imarai M, Acuña-Castillo C. Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group. Front Immunol. 2022 Jan 31;12:766278. doi: 10.3389/fimmu.2021.766278
dc.identifier.doihttps://doi.org/10.3389/fimmu.2021.766278
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7431
dc.language.isoen
dc.subjectCoronaVac
dc.subjectSARS-CoV-2
dc.subjectHerd immunity
dc.subjectNeutralizing antibodies
dc.subjectCOVID-19
dc.subjectVaccine
dc.subjectImmunologicalmemory
dc.titleEvaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceFrontiers in immunology
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
4. Evaluation of the Immune Response.pdf
Size:
3.49 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services